As per Global Insight services’ assessment, about 20+ prominent pharma and biotech giants are working on 20+ drugs in the Atrial Fibrillation – Drug Pipeline Landscape, 2023 globally. Atrial Fibrillation – Drug Pipeline Landscape, 2023 report by Global Insight Services provides a comprehensive analysis of the ongoing clinical development activities and growth prospect.
“Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key –https://www.globalinsightservices.com/request-sample/GIS31160
Atrial fibrillation is a type of cardiac arrhythmia acclaimed by an anomalous cardiac rhythm element by a disturbance in heart’s electrical system. There are three types of atrial fibrillation Paroxysmal atrial fibrillation, Persistent atrial fibrillation, Long-standing persistent atrial fibrillation.
Causes of atrial fibrillation are augmentation of blood clots within the upper chambers of the heart and age, heart disease, high blood pressure, family history and drinking alcohol.
Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain.
Atrial fibrillation is diagnosed by electrocardiogram (ECG or EKG), blood tests, holter monitor, chest X-ray.
Atrial fibrillation is treated by lifestyle changes and drugs like potassium channel blockers, beta-blockers and calcium channel blockers.
Free customization available – https://www.globalinsightservices.com/request-customization/GIS31160
There are many clinical trials currently ongoing in atrial fibrillation drug development. Some of the most promising trials are studying new ways to prevent or treat atrial fibrillation, including new drugs, devices, and surgical procedures. Many of these trials are still in the early stages, but they offer hope for better treatments for this common and potentially deadly condition.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Atrial Fibrillation treatment such as Xeomin, Abelacimab, HSY244, and others. Key players involved in the development of therapies to treat Atrial Fibrillation are AbbVie Inc, Bayer, Novartis, and others. Two drugs are under Phase III clinical trials and 10+ drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
Buy your copy now: https://www.globalinsightservices.com/checkout/single_user/GIS31160
Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage product (Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/